✦ LIBER ✦

Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients

✍ Scribed by Reardon, David A.; Conrad, Charles A.; Cloughesy, Timothy; Prados, Michael D.; Friedman, Henry S.; Aldape, Kenneth D.; Mischel, Paul; Xia, Jane; DiLea, Clifford; Huang, Jerry; Mietlowski, William; Dugan, Margaret; Chen, Wei; Yung, W. K. Alfred

Book ID: 113028081
Publisher: Springer
Year: 2012
Tongue: English
Weight: 416 KB
Volume: 69
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-012-1854-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

387 A phase I study of AEE788, a novel m

387 A phase I study of AEE788, a novel multi-targeted inhibitor of ErbB and VEGF receptor family tyrosine kinases

✍ H. Dumez; P. Clement; C.H. Takimoto; A.T. van Oosterom; A. Mita; K. Parker; E.K. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 147 KB

412 A phase I and pharmacokinetic study

412 A phase I and pharmacokinetic study of AEE788, a novel multi-targeted inhibitor of ErbB and VEGF receptor family tyrosine kinases

✍ A. Mita; C.H. Takimoto; E. Martinelli; H. Dumez; C. DiLea; W. Mietlowski; J. Tab 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 149 KB

621 POSTER A phase I study of combinatio

621 POSTER A phase I study of combination therapy with AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, and RAD001, a mTOR inhibitor in recurrent GBM patients

✍ D. Reardon; T. Cloughesy; J. Rich; W. Yung; C. Cilea; W. Mietlowski; L. Yung; W. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 53 KB

367 Emerging pharmacokinetic (PK)-pharma

367 Emerging pharmacokinetic (PK)-pharmacodynamic (PD) profile of AEE788, a novel multi-targeted inhibitor of ErbB and VEGF receptor family tyrosine kinases

✍ J. Baselga; F. Rojo; A. van Oosterom; H. Dumez; J. Huang; E. Walk; A. Mita; E. R 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 284 KB

P-359 Results from a phase I study of th

P-359 Results from a phase I study of the oral VEGF receptor tyrosine kinase inhibitor ZD6474, in patients with solid tumors

✍ Wheeler, Catherine; Minami, Hironobu; Ebi, Hiromichi; Tahara, Makoto; Sasaki, Ya 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 189 KB

Effects of ZD6474, an orally active inhi

Effects of ZD6474, an orally active inhibitor of VEGF receptor tyrosine kinase, in patients with solid tumors: Results from a phase I study

✍ S. Holden; S. Eckhardt; R. Basser; D. Rischin; H. Hurwitz; R. DeBoer; M. Rosenth 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 189 KB